BioCentury
ARTICLE | Clinical News

AS1411: Interim Phase II data

December 22, 2008 8:00 AM UTC

Interim data from 28 evaluable patients in the open-label, U.S. Phase II AS1411-C-201 trial showed that 10 mg/kg/day AS1411 plus cytarabine produced 2 CRS, 1 CR with incomplete platelet recovery (CRp)...